These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20942471)

  • 1. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis.
    Laleu B; Gaggini F; Orchard M; Fioraso-Cartier L; Cagnon L; Houngninou-Molango S; Gradia A; Duboux G; Merlot C; Heitz F; Szyndralewiez C; Page P
    J Med Chem; 2010 Nov; 53(21):7715-30. PubMed ID: 20942471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.
    Gaggini F; Laleu B; Orchard M; Fioraso-Cartier L; Cagnon L; Houngninou-Molango S; Gradia A; Duboux G; Merlot C; Heitz F; Szyndralewiez C; Page P
    Bioorg Med Chem; 2011 Dec; 19(23):6989-99. PubMed ID: 22041175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput screening for reactive oxygen species scavengers targeting mitochondria.
    Chen XP; Du GH
    Methods Find Exp Clin Pharmacol; 2008 May; 30(4):255-60. PubMed ID: 18773119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
    Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
    J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist.
    Ito S; Satoh A; Nagatomi Y; Hirata Y; Suzuki G; Kimura T; Satow A; Maehara S; Hikichi H; Hata M; Kawamoto H; Ohta H
    Bioorg Med Chem; 2008 Nov; 16(22):9817-29. PubMed ID: 18849168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NADPH oxidase inhibitors: a patent review.
    Kim JA; Neupane GP; Lee ES; Jeong BS; Park BC; Thapa P
    Expert Opin Ther Pat; 2011 Aug; 21(8):1147-58. PubMed ID: 21554154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
    Koike T; Takai T; Hoashi Y; Nakayama M; Kosugi Y; Nakashima M; Yoshikubo S; Hirai K; Uchikawa O
    J Med Chem; 2011 Jun; 54(12):4207-18. PubMed ID: 21568291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
    Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
    Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis.
    Crestani B; Besnard V; Boczkowski J
    Int J Biochem Cell Biol; 2011 Aug; 43(8):1086-9. PubMed ID: 21513813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOX1/NADPH oxidase negatively regulates nerve growth factor-induced neurite outgrowth.
    Ibi M; Katsuyama M; Fan C; Iwata K; Nishinaka T; Yokoyama T; Yabe-Nishimura C
    Free Radic Biol Med; 2006 May; 40(10):1785-95. PubMed ID: 16678016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
    Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
    J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells.
    Jaulmes A; Sansilvestri-Morel P; Rolland-Valognes G; Bernhardt F; Gaertner R; Lockhart BP; Cordi A; Wierzbicki M; Rupin A; Verbeuren TJ
    Thromb Res; 2009 Sep; 124(4):439-46. PubMed ID: 19540572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
    Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
    J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
    Jia ZJ; Wu Y; Huang W; Zhang P; Song Y; Woolfrey J; Sinha U; Arfsten AE; Edwards ST; Hutchaleelaha A; Hollennbach SJ; Lambing JL; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1229-34. PubMed ID: 14980671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
    Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
    J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.